GO:0031771 type 1 orexin receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031771 (type 1 orexin receptor binding) is a molecular function describing the binding of a ligand to the type 1 orexin receptor (OX1R), a G-protein-coupled receptor.
• The term is defined by QuickGO as 'Binding to a type 1 orexin receptor' and includes synonyms such as OX1 orexin receptor binding and type 1 hypocretin receptor binding.
• OX1R couples exclusively to pertussis toxin-insensitive G-proteins, distinguishing it from OX2R, which couples to both pertussis toxin-sensitive and -insensitive G-proteins.
• Orexin receptor binding is implicated in arousal, stress, and sleep regulation, with selective OX1R antagonists attenuating stress-induced hyperarousal without hypnotic effects.
• In colon cancer cell models, OX1R antagonism can have a two-sided nature due to partial dissociation of Gq, highlighting context-dependent signaling.
• Microglia density and orexin levels are associated with disease duration and severity in narcolepsy type 1, linking orexin biology to neuroinflammation.
Description
GO:0031771, type 1 orexin receptor binding, is a molecular function term in the Gene Ontology that describes the binding of a ligand to the type 1 orexin receptor (OX1R). This receptor is a G-protein-coupled receptor (GPCR) that plays a central role in sleep-wake regulation, arousal, and stress responses. The term is part of the broader orexin/hypocretin signaling system, which is critical for maintaining wakefulness and energy homeostasis. Researchers study this binding event to understand how orexin neuropeptides modulate neuronal activity and to develop therapeutics for sleep disorders and other conditions. The specificity of OX1R binding is underscored by its exclusive coupling to pertussis toxin-insensitive G-proteins, unlike OX2R, which couples to both pertussis toxin-sensitive and -insensitive G-proteins. This distinction makes OX1R an attractive target for selective pharmacological intervention. In colon cancer cell models, OX1R antagonism exhibits a two-sided nature due to partial dissociation of Gq, revealing complex pharmacodynamics that depend on ligand-receptor interactions. Additionally, microglia density and orexin levels are associated with disease duration and severity in narcolepsy type 1, suggesting a link between orexin receptor binding and neuroinflammatory processes. Understanding the molecular details of type 1 orexin receptor binding is therefore essential for both basic neuroscience and translational research.
type 1 orexin receptor binding At A Glance
| GO ID | GO:0031771 |
|---|---|
| GO term | type 1 orexin receptor binding |
| Ontology | molecular_function |
| Synonym | OX1 orexin receptor binding; type 1 hypocretin receptor binding; type 1 hypocretin receptor ligand |
| Major function | Binding to the type 1 orexin receptor (OX1R), initiating downstream signaling |
| Receptor type | G-protein-coupled receptor (GPCR) |
| Primary ligands | Orexin-A and orexin-B (hypocretin-1 and hypocretin-2) |
| G-protein coupling | Pertussis toxin-insensitive G-proteins |
| Associated diseases | Narcolepsy type 1, insomnia, stress-related disorders, colon cancer |
What Is GO:0031771?
Type 1 orexin receptor binding (GO:0031771) is the molecular function of a ligand physically interacting with the type 1 orexin receptor (OX1R). According to the Gene Ontology, it is defined as 'Binding to a type 1 orexin receptor.' This term encompasses the initial recognition event between an orexin neuropeptide (or synthetic ligand) and the OX1R protein, which is a class A GPCR. The binding event is a prerequisite for downstream signal transduction, including G-protein activation and intracellular calcium mobilization. Synonyms include OX1 orexin receptor binding, type 1 hypocretin receptor binding, and type 1 hypocretin receptor ligand. The term is used to annotate gene products that act as ligands for OX1R, such as the orexin-A and orexin-B peptides, as well as synthetic antagonists and agonists.
Why Is type 1 orexin receptor binding Important in Cell Biology?
Type 1 orexin receptor binding is critically important because it represents the first step in orexin signaling, a pathway that regulates wakefulness, arousal, and energy balance. Dysregulation of this binding event is implicated in sleep disorders such as narcolepsy type 1 and insomnia, as well as in stress-related hyperarousal. The receptor's unique coupling to pertussis toxin-insensitive G-proteins makes it a selective target for drug development, with antagonists showing potential for treating insomnia without hypnotic side effects. Furthermore, OX1R binding has been observed in cancer cell models, where antagonism can have complex, two-sided effects due to partial Gq dissociation, underscoring the need for detailed mechanistic studies. Understanding this binding event at the molecular level is essential for designing selective therapeutics and for interpreting pharmacological data across different tissues.
• Regulates sleep-wake cycles and arousal through orexin signaling.
• Selective OX1R antagonists attenuate stress-induced hyperarousal without hypnotic effects.
• Implicated in narcolepsy type 1, where microglia density and orexin levels correlate with disease severity.
• Target for insomnia therapies, with emerging drugs focusing on orexin receptor modulation.
• Shows context-dependent pharmacology in colon cancer cells, with partial Gq dissociation affecting antagonist efficacy.
• Distinct G-protein coupling profile (pertussis toxin-insensitive) enables selective targeting.
• Binding event is a prerequisite for downstream calcium signaling and neuronal excitation.
• Relevant to neuroinflammation, as microglia density associates with orexin levels in narcolepsy.
• Provides a model for studying GPCR ligand binding and biased signaling.
• Potential biomarker for diseases involving orexin dysregulation.
Molecular Mechanism of type 1 orexin receptor binding
Ligand Recognition and Binding Pocket
In simple terms: The orexin ligand fits into a specific pocket on the OX1R receptor like a key in a lock.
The type 1 orexin receptor (OX1R) binds orexin-A and orexin-B with high affinity. The binding pocket is formed by transmembrane helices and extracellular loops of the GPCR. Molecular dynamics simulations of related orexin receptors have revealed non-canonical Gq activation mechanisms, suggesting that ligand binding induces conformational changes that propagate to the intracellular side. The SK-N-MC cell line expresses an orexin binding site that differs from recombinant OX1R, indicating that native receptor context can influence binding properties.
G-Protein Coupling Selectivity
In simple terms: Once the ligand binds, the receptor activates specific G-proteins inside the cell.
OX1R couples exclusively to pertussis toxin-insensitive G-proteins, whereas OX2R couples to both pertussis toxin-sensitive and -insensitive G-proteins. This selectivity is a key determinant of downstream signaling and cellular responses. The binding event triggers GDP-GTP exchange on G-alpha subunits, leading to activation of phospholipase C and calcium release.
Partial Dissociation of Gq and Two-Sided Antagonism
In simple terms: Some drugs can block the receptor in unexpected ways, sometimes even activating it partially.
In colon cancer cell models, antagonistic ligands for OX1R exhibit a two-sided nature resulting from partial dissociation of Gq. This means that antagonists can have variable effects depending on the cellular context and the stability of the ligand-receptor-G-protein complex. Such pharmacodynamics highlight the complexity of targeting OX1R and the need for detailed binding studies.
Regulation by Microenvironment and Disease State
In simple terms: The surrounding cells and disease conditions can change how the receptor binds and signals.
Microglia density and orexin levels are associated with disease duration and severity in narcolepsy type 1, suggesting that neuroinflammatory cells may influence orexin receptor binding or signaling. This implies that the binding event is not isolated but modulated by the tissue microenvironment.
Key Genes Involved in GO:0031771 type 1 orexin receptor binding
The following genes and proteins are directly involved in type 1 orexin receptor binding and its downstream signaling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HCRT | Encodes orexin-A and orexin-B neuropeptides | Ligands for OX1R; mutations linked to narcolepsy |
| HCRTR1 | Encodes the type 1 orexin receptor (OX1R) | Primary receptor for GO:0031771; target for antagonists |
| HCRTR2 | Encodes the type 2 orexin receptor (OX2R) | Related receptor with different G-protein coupling |
| GNAQ | G-alpha q subunit | Mediates OX1R signaling; partial dissociation in cancer |
| GNA11 | G-alpha 11 subunit | Alternative Gq family member coupled to OX1R |
| PLCB1 | Phospholipase C beta 1 | Downstream effector of Gq signaling |
| ITPR1 | Inositol 1,4,5-trisphosphate receptor | Mediates calcium release upon OX1R activation |
| PRKCA | Protein kinase C alpha | Downstream kinase activated by DAG |
| CAMK2A | Calcium/calmodulin-dependent protein kinase II alpha | Neuronal signaling downstream of calcium |
| SLC6A4 | Serotonin transporter | Modulated by orexin signaling in arousal circuits |
| TH | Tyrosine hydroxylase | Rate-limiting enzyme in dopamine synthesis; affected by orexin |
| DBH | Dopamine beta-hydroxylase | Norepinephrine synthesis; linked to arousal |
| GAD1 | Glutamate decarboxylase 1 | GABA synthesis; orexin modulates GABAergic neurons |
| SLC17A6 | Vesicular glutamate transporter 2 | Glutamatergic signaling in orexin neurons |
| GFAP | Glial fibrillary acidic protein | Astrocyte marker; glia influence orexin signaling |
| CX3CR1 | Fractalkine receptor | Microglia marker; microglia density correlates with orexin levels |
| TNF | Tumor necrosis factor | Neuroinflammatory cytokine; may affect orexin neurons |
| IL1B | Interleukin 1 beta | Inflammatory mediator linked to sleep regulation |
How Is type 1 orexin receptor binding Regulated?
The binding of ligands to the type 1 orexin receptor is regulated at multiple levels. Receptor expression levels can be modulated by disease states, as seen in narcolepsy type 1 where orexin levels and microglia density are altered. Ligand availability is controlled by the synthesis and release of orexin neuropeptides from hypothalamic neurons. Additionally, the binding event can be influenced by the local lipid environment and interacting proteins. Pharmacological regulation includes competitive antagonists such as selective OX1R antagonists that block binding and attenuate stress-induced hyperarousal. In cancer cells, partial dissociation of Gq can lead to complex regulation of antagonist efficacy. Post-translational modifications of the receptor, such as phosphorylation, may also regulate its binding affinity and signaling.
type 1 orexin receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HCRTR1 | Narcolepsy type 1, insomnia | Hcrtr1 knockout mouse; sleep-wake EEG recordings |
| HCRT | Narcolepsy type 1 | Hcrt knockout mouse; orexin neuron ablation |
| HCRTR1 | Colon cancer | Human colon cancer cell lines (e.g., HCT116) with OX1R overexpression |
| HCRTR1 | Stress-related disorders | Chronic stress models in rodents with OX1R antagonist treatment |
| CX3CR1 | Neuroinflammation in narcolepsy | Cx3cr1-GFP reporter mice; microglia density analysis |
Narcolepsy Type 1
Narcolepsy type 1 is characterized by the loss of orexin-producing neurons, leading to reduced orexin levels. Microglia density is associated with disease duration and severity, and orexin levels correlate with microglial activation, suggesting that neuroinflammation may influence type 1 orexin receptor binding and signaling. The binding of orexin to OX1R is critical for maintaining wakefulness, and its dysfunction contributes to excessive daytime sleepiness and cataplexy.
Insomnia and Sleep Disorders
Insomnia therapies increasingly target orexin receptors. Selective OX1R antagonists can attenuate stress-induced hyperarousal without hypnotic effects, offering a novel approach for treating insomnia. Emerging and upcoming therapies in insomnia include dual orexin receptor antagonists (DORAs) and selective OX1R antagonists, which block the binding of orexin to its receptors.
Colon Cancer
In colon cancer cell models, OX1R antagonism exhibits a two-sided nature due to partial dissociation of Gq. This suggests that OX1R binding and signaling can have context-dependent effects on cancer cell proliferation and survival. The presence of orexin receptors in cancer cells highlights potential repurposing of orexin receptor ligands for oncology.
Stress-Related Disorders
Orexin signaling is implicated in stress responses. Selective OX1R antagonists attenuate stress-induced hyperarousal without hypnotic effects, indicating that type 1 orexin receptor binding plays a role in anxiety and stress-related behaviors. This has implications for developing treatments for post-traumatic stress disorder and panic disorders.
From type 1 orexin receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does OX1R mediate arousal? | Hcrtr1 knockout mouse with sleep-wake monitoring |
| How does a point mutation affect ligand binding? | HCRTR1 point-mutant knock-in cell lines (e.g., HEK293T) |
| Can we visualize OX1R trafficking? | Tagged knock-in of HCRTR1 with fluorescent protein in neurons |
| What is the effect of OX1R overexpression in cancer? | Colon cancer cell lines with doxycycline-inducible HCRTR1 overexpression |
| Which genes interact with OX1R? | CRISPR library screening in OX1R-expressing cells |
| Does OX1R antagonism affect stress behavior? | Conditional Hcrtr1 knockout in specific brain regions |
How to Study the type 1 orexin receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Affinity and kinetics of ligand-receptor interaction | Characterizing OX1R antagonists |
| Calcium mobilization | Gq-mediated signaling | Assessing agonist/antagonist efficacy |
| Molecular dynamics | Conformational changes and G-protein coupling | Understanding non-canonical activation |
| CRISPR knockout | Loss-of-function effects | Validating OX1R role in arousal |
| CRISPR knock-in | Tagged receptor localization and function | Imaging OX1R trafficking |
| RNA-seq | Transcriptional changes upon OX1R activation | Identifying downstream pathways |
| Proteomics | Protein-protein interactions | Discovering OX1R binding partners |
| Immunohistochemistry | Receptor expression and microglia density | Narcolepsy brain tissue analysis |
Radioligand Binding Assays
Radioligand binding assays using tritiated orexin-A or selective antagonists are used to measure the affinity and kinetics of type 1 orexin receptor binding. These assays can be performed on cell membranes expressing recombinant OX1R or on native tissues. The SK-N-MC cell line has been used to characterize orexin binding sites, revealing differences from recombinant OX1R.
Molecular Dynamics Simulations
Molecular dynamics simulations, such as those performed on orexin receptor type 2, can reveal non-canonical Gq activation mechanisms and ligand-induced conformational changes. These simulations provide atomic-level insights into the binding process and can guide drug design.
Calcium Mobilization Assays
Calcium mobilization assays using fluorescent dyes (e.g., Fluo-4) measure downstream signaling upon OX1R binding. This method is useful for assessing agonist and antagonist potency in live cells, including cancer cell models where partial Gq dissociation affects responses.
CRISPR-Cas9 Genome Editing
CRISPR-Cas9 can be used to knock out HCRTR1 or introduce point mutations to study the effects on ligand binding and signaling. Knock-in of tagged receptors enables imaging and proteomic studies. These approaches are essential for dissecting the molecular determinants of type 1 orexin receptor binding.
How CRISPR Can Be Used to Study GO:0031771 type 1 orexin receptor binding
Knockout
CRISPR-Cas9 knockout of HCRTR1 in cell lines or animal models abolishes type 1 orexin receptor binding, allowing researchers to study loss-of-function phenotypes such as altered sleep-wake cycles or stress responses. Knockout models are essential for validating the specific contribution of OX1R to arousal and energy balance.
Point Mutation
Introducing point mutations in HCRTR1 via CRISPR base editing or homology-directed repair can dissect the binding pocket residues critical for orexin-A versus orexin-B recognition. Such models help identify residues responsible for G-protein coupling selectivity and partial Gq dissociation.
Knock-in
Knock-in of fluorescent or epitope tags into the endogenous HCRTR1 locus enables real-time imaging and proteomic analysis of the receptor in its native context. This approach preserves endogenous regulatory elements and provides accurate spatial and temporal expression patterns.
Overexpression
Overexpression of HCRTR1 in cell lines (e.g., HEK293T, colon cancer cells) using CRISPR activation or lentiviral vectors increases receptor density, facilitating biochemical assays such as radioligand binding and calcium mobilization. Overexpression models are useful for studying gain-of-function effects and drug screening.
How EDITGENE Supports type 1 orexin receptor binding Research
Researchers studying type 1 orexin receptor binding-related genes often need to determine whether a candidate gene is causally involved in receptor function, signaling, or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from knockout to precise point mutations and library screening.
Contact EDITGENE today to design your custom CRISPR model for type 1 orexin receptor binding research.
Frequently Asked Questions About type 1 orexin receptor binding
What is type 1 orexin receptor binding?
Type 1 orexin receptor binding (GO:0031771) is the molecular function of a ligand binding to the type 1 orexin receptor (OX1R), a G-protein-coupled receptor involved in sleep and arousal.
What genes are involved in type 1 orexin receptor binding?
Key genes include HCRTR1 (encoding OX1R), HCRT (encoding orexin ligands), and downstream signaling genes such as GNAQ and PLCB1.
What diseases are associated with type 1 orexin receptor binding?
Narcolepsy type 1, insomnia, stress-related disorders, and colon cancer have been linked to orexin receptor binding and signaling.
How does OX1R differ from OX2R?
OX1R couples exclusively to pertussis toxin-insensitive G-proteins, while OX2R couples to both pertussis toxin-sensitive and -insensitive G-proteins.
What are the research methods to study type 1 orexin receptor binding?
Common methods include radioligand binding assays, calcium mobilization, molecular dynamics simulations, and CRISPR-based genome editing.
Can CRISPR be used to study type 1 orexin receptor binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect the function of HCRTR1 and interacting genes.
What is the role of microglia in narcolepsy type 1?
Microglia density is associated with disease duration and severity, and orexin levels correlate with microglial activation in narcolepsy type 1.
Are there selective OX1R antagonists?
Yes, selective OX1R antagonists such as those described by Bonaventure et al. attenuate stress-induced hyperarousal without hypnotic effects.
How does partial Gq dissociation affect OX1R antagonism?
In colon cancer cells, partial dissociation of Gq leads to two-sided effects of antagonistic ligands, meaning antagonists can have variable efficacy.
What is the clinical relevance of orexin receptor binding?
It is relevant for developing therapies for insomnia, narcolepsy, and potentially cancer, as orexin signaling influences sleep, arousal, and cell proliferation.
Conclusion
Type 1 orexin receptor binding (GO:0031771) is a fundamental molecular event that initiates orexin signaling, a pathway critical for sleep-wake regulation, stress responses, and energy balance. Its unique pharmacological profile, including exclusive coupling to pertussis toxin-insensitive G-proteins and context-dependent antagonism, makes it a compelling target for therapeutic development. Research into this binding event continues to reveal insights into narcolepsy, insomnia, and cancer, underscoring the importance of precise mechanistic studies. EDITGENE's CRISPR services provide the tools needed to dissect the genetic and molecular underpinnings of type 1 orexin receptor binding, accelerating discoveries that may lead to novel treatments.
References
- 2. Gratio V et al.. 2025. Pharmacodynamics of the orexin type 1 (OX(1)) receptor in colon cancer cell models: A two-sided nature of antagonistic ligands resulting from partial dissociation of Gq.. Br J Pharmacol 182(7):1528-1545 PMID: 39675769
- 3. Barateau L et al.. 2024. Microglia Density and Its Association With Disease Duration, Severity, and Orexin Levels in Patients With Narcolepsy Type 1.. Neurology 102(10):e209326 PMID: 38669634
- 4. Dragan P et al.. 2025. Non-canonical G(q) activation by orexin receptor type 2 and lemborexant observed in microsecond molecular dynamics simulations.. Sci Rep 15(1):30899 PMID: 40846858
- 5. Bonaventure P et al.. 2015. A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects.. J Pharmacol Exp Ther 352(3):590-601 PMID: 25583879
- 6. Wieland HA et al.. 2002. The SK-N-MC cell line expresses an orexin binding site different from recombinant orexin 1-type receptor.. Eur J Biochem 269(4):1128-35 PMID: 11856342
- 7. Kim WJ et al.. 2024. Emerging and upcoming therapies in insomnia.. Transl Clin Pharmacol 32(1):1-17 PMID: 38586124
- 8. Zhu Y et al.. 2003. Orexin receptor type-1 couples exclusively to pertussis toxin-insensitive G-proteins, while orexin receptor type-2 couples to both pertussis toxin-sensitive and -insensitive G-proteins.. J Pharmacol Sci 92(3):259-66 PMID: 12890892
